Home › Research › Costs and economics
Monetary Costs of Dementia in the United States
Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. New England Journal of Medicine, 2013-04-04
Topic: Risk, prevention and care in population studies
Plain-language summary
Using a nationally representative survey of older Americans with in-home cognitive testing, researchers estimated that dementia cost the US between $157 billion and $215 billion in 2010, depending on how unpaid family caregiving time is valued. That made dementia more expensive nationally than heart disease or cancer. Nursing home care and paid or unpaid home care together made up 75-84% of the total cost.
What this study adds
Evidence grade: High
This is a follow-up (cohort) study of 856 participants. Dementia cost the US between $157 billion and $215 billion in 2010, making it more expensive nationally than heart disease or cancer. Its stated limit: Cost estimates were highly sensitive to the method used to monetarily value unpaid family caregiving time, and the core dementia diagnosis relied on a relatively small clinically assessed subsample (n=856) statistically imputed to the larger survey population.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013). Monetary Costs of Dementia in the United States. New England Journal of Medicine. https://doi.org/10.1056/nejmsa1204629
Vancouver
Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary Costs of Dementia in the United States. New England Journal of Medicine. 2013. doi:10.1056/nejmsa1204629. PMID: 23550670.
BibTeX
@article{hurd2013-6ad13be5,
author = {Hurd, M. D. and Martorell, P. and Delavande, A. and Mullen, K. J. and Langa, K. M.},
title = {{Monetary Costs of Dementia in the United States}},
journal = {New England Journal of Medicine},
year = {2013},
doi = {10.1056/nejmsa1204629},
pmid = {23550670},
url = {https://doi.org/10.1056/nejmsa1204629}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Total 2010 US monetary cost of dementia estimated at $157-$215 billion depending on informal-care valuation method
- Per-person annual cost estimated at $41,689-$56,290 depending on valuation method
- Nursing home care plus formal and informal home care made up 75-84% of total dementia costs
- Dementia was found to be more costly nationally than heart disease or cancer
Why it matters
Dementia cost the US between $157 billion and $215 billion in 2010, making it more expensive nationally than heart disease or cancer. Nursing home care and paid or unpaid home care together made up 75-84% of the total cost.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designcohort
- Participants856
- Effect sizeAnnual per-person cost of $56,290 (95% CI $42,746-$69,834) using replacement-cost valuation of informal care, or $41,689 (95% CI $31,017-$52,362) using forgone-wages valuation; total 2010 national cost of $157-$215 billion, exceeding costs for heart disease or cancer
- Evidence strengthHigh
Limitations
Cost estimates were highly sensitive to the method used to monetarily value unpaid family caregiving time, and the core dementia diagnosis relied on a relatively small clinically assessed subsample (n=856) statistically imputed to the larger survey population.
How this study scored 69/100
Published in a top-tier journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 43 of the 62 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (New England Journal of Medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 856 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23550670) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 43 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 62 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
103 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Costs and economics from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.